



Case report

Hyponatremia in refractory congestive heart failure patients treated with icodextrin-based peritoneal dialysis: A case series

Margarita Kunin*, Liat Ganon, Eli J. Holtzman, Dganit Dinour

Nephrology and Hypertension Institute, Sheba Medical Center and Sackler Faculty of Medicine, Tel-Hashomer, Israel

ARTICLE INFO

Article history:

Received 21 November 2016

Accepted 2 May 2017

Available online 29 July 2017

Keywords:

Hyponatremia

Congestive heart failure

Peritoneal dialysis

ABSTRACT

Severe congestive heart failure (CHF) patients are prone to hyponatremia. Peritoneal dialysis (PD) is increasingly used for long-term management of refractory CHF patients. The glucose polymer icodextrin was proposed to be a good option for fluid removal in such patients. A small, although statistically significant reduction in serum sodium (~2 mmol/l) consistently observed in multiple trials, is considered as not clinically relevant. Here we reported five refractory CHF patients who demonstrated sodium drop by median of 8 meq/l (range 5.4–8.3 meq/l) after icodextrin was added to their program. It seems that icodextrin may contribute to clinically relevant hyponatremia if the hyponatremia is compounded by other factors. Patients with extremely severe congestive heart failure are susceptible to this complication.

© 2017 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Hiponatremia en pacientes con insuficiencia cardíaca congestiva resistentes al tratamiento tratados con diálisis peritoneal con icodextrina: una serie de casos

RESUMEN

Los pacientes con insuficiencia cardíaca congestiva grave son propensos a sufrir hiponatremia. La diálisis peritoneal se utiliza cada vez más para el tratamiento a largo plazo de los pacientes con insuficiencia cardíaca congestiva resistentes al tratamiento. El polímero de glucosa icodextrina se propuso como una buena opción para la ultrafiltración. Una reducción pequeña, aunque estadísticamente significativa, del sodio sérico (~2 mmol/l) observada sistemáticamente en numerosos ensayos no se considera de relevancia clínica. En este documento informamos de 5 casos de pacientes con insuficiencia cardíaca congestiva resistentes al tratamiento que presentaron una caída de las concentraciones de sodio en una mediana

Palabras clave:

Hiponatremia

Insuficiencia cardíaca congestiva

Diálisis peritoneal

* Corresponding author.

E-mail address: Margarita.Kunin@sheba.health.gov.il (M. Kunin).

<https://doi.org/10.1016/j.nefro.2017.05.010>

0211-6995/© 2017 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

de 8 mEq/l (intervalo 5,4-8,3 mEq/l) después de la adición de icodextrina a su programa. Parece ser que la icodextrina puede contribuir a una hiponatremia clínicamente relevante si se combina con otros factores. Los pacientes con insuficiencia cardíaca congestiva muy grave son propensos a esta complicación.

© 2017 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Removal of extensive fluid overload is one of the most difficult challenges in the management of severe congestive heart failure (CHF), particularly in patients who do not respond to diuretic therapy. Peritoneal ultrafiltration (UF) is a simple choice for daily fluid removal. Today, peritoneal dialysis (PD) is increasingly used to treat hypervolemic CHF patients who are resistant to conventional therapies, in particular when complicated by renal insufficiency (reviewed in Refs. 1, 2). Icodextrin was proposed to be a good option for UF in refractory CHF patients.³⁻⁶ Icodextrin solution is a long-acting osmotic agent that allows the patient's UF volume to gradually increase for up to 12 h.^{1,3} In a recently published systematic review⁷ it was found that mortality in CHF patients treated with peritoneal UF was associated with less use of icodextrin.

Icodextrin is generally well tolerated. A small, although statistically significant reduction in serum sodium (~2 mmol/l) consistently observed in multiple trials, is likely not clinically relevant.⁸ Two female diabetic patients treated by icodextrin-based PD developed severe hyponatraemia with plasma Na < 121 mmol/l and neurological complications.⁹ The mechanism by which icodextrin causes hyponatremia is unclear. It was proposed that icodextrin solution leads to accumulation of maltose in the extracellular volume and this gradient induces osmotic flow by a mechanism similar to isosmolar colloid osmosis. The resultant shift in water from the intracellular to the extracellular space can result in dilutional hyponatremia.⁸ It was demonstrated that icodextrin increased peritoneal Na removal.¹⁰

Five refractory CHF patients treated with peritoneal ultrafiltration in our unit, developed significant symptomatic hyponatremia with Na < 130 mmol/l after icodextrin was added to their program (Table 1).

Cases description

Patient 1

A 63-year-old woman with history of diabetes mellitus (DM), restrictive cardiomyopathy and severe pulmonary hypertension was referred to PD due to significant volume overload. Her eGFR was 27 ml/min/1.73 m². She had no proteinuria and renal sonography showed small kidneys. Her kidney disease was attributed to nephrosclerosis with cardiorenal component. She was treated with one dianeal glucose solution 4.25% exchange per day for 6 weeks, then icodextrin was added to her program. She continued the treatment with furosemide

and was on sodium restriction diet. Her urinary sodium at icodextrin start was 78 meq/l. Following icodextrin start a serum sodium dropped from 136.3 to 128.3 meq/l (average of 3 consecutive values) with the lowest value measured of 126 meq/l. The patient complained of extreme weakness and fatigue. Icodextrin was stopped and dianeal glucose solution 2.5% was started. After icodextrin stop serum sodium raised to 134.7 meq/l (average of 3 consecutive values). Due to difficulty to maintain adequate ultrafiltration and worsening diabetes mellitus control, icodextrin was restarted. Serum sodium dropped to 128.7 meq/l (average of 3 consecutive values), lowest value measured was 128 meq/l. The patient complained of extreme weakness and fatigue, therefore icodextrin was stopped again. A month later average serum sodium was 133 meq/l. The patient died a month later from heart failure exacerbation.

Patient 2

A 64-year-old woman with hypertrophic cardiomyopathy was referred to PD due to significant volume overload. She had no proteinuria and demonstrated normal kidneys in renal sonography. Her kidney disease was attributed to cardiorenal syndrome. At PD start the patient's eGFR was 23 ml/min/1.73 m². From the very beginning she turned to be hypotensive and oliguric. The patient was 8 months on PD with 3 glucose 2.5% exchanges per day. Furosemide was stopped due to oliguria and hypotension. Urinary sodium was 49 meq/l and the patient continued to be edematous. After icodextrin addition serum sodium dropped from 133.7 to 126.3 meq/l (average of 3 consecutive values) with the lowest value measured of 125 meq/l. The patient continued with icodextrin despite low serum sodium. Non-adherence to free water restriction was suspected. Despite the attempts to restrict free water consumption by the patient serum sodium remained low. The patient died 5 months later from septic shock due to infected cardiac pacemaker electrode.

Patient 3

An 82-year-old man with ischemic cardiomyopathy and low LVEF started PD due to resistant volume overload. At the admission his eGFR was 26 ml/min/1.73 m². He had non-nephrotic proteinuria and reduced parenchyma size in kidney sonography. His renal disease was attributed to nephrosclerosis with cardiorenal component. He was treated with PD for one month with 2 exchanges per day: glucose 2.5% and glucose 4.25%. He continued treatment with furosemide and was on sodium restriction diet. His urinary sodium was 53 meq/l. After icodextrin addition serum sodium dropped from 134.7

Table 1 – Cases of severe hyponatremia following icodextrin treatment.

	Case 1	Case 2	Case 3	Case 4	Case 5
Age, years	63	64	82	75	85
Sex	f	f	m	f	m
Etiology of heart disease	Restrictive cardiomyopathy	Hypertrophic cardiomyopathy	Ischemic cardiomyopathy	Primary pulmonary hypertension	Ischemic cardiomyopathy
Etiology of renal disease	Nephrosclerosis	Cardiorenal	Nephrosclerosis	Cardiorenal	Cardiorenal
Diabetes mellitus	Yes	No	No	No	Yes
Baseline serum sodium (meq/l)	136.3	133.7	134.7	137.3	138.3
Serum sodium (meq/l) 1 month after icodextrin start	128.3	126.3	129.3	129	130
Serum glucose (mg/dL) 1 month after icodextrin start	160	114.3	192.3	118.7	232.3
Baseline serum creatinine (mg/dL)	3.26	3.76	4.1	2.46	2.65
Baseline serum albumin (g/dL)	3.1	3.3	3.7	2.9	3
LVEF (%)	60	50	20	70	20
Estimated SPAP (mmHg)	88	56	43	92	76
Diuretics	Furosemide	No	Furosemide	Furosemide	Furosemide
Other solutions (L/day)	4.25% – 2L	2.5% - 6L	4.25% – 2L 2.5% – 2L	4.25% – 2L	4.25% – 2L
Clinical symptoms	Restlessness, muscle weakness	Confusion	Confusion, hip fracture	Confusion, hip fracture	Weakness, fatigue

to 129.3 meq/l (average of 3 consecutive values) with the lowest value measured of 127 meq/l. The patient continued with icodextrin despite low serum sodium. He was diagnosed with hip fracture without the history of trauma or fall. He did not recover from the surgery and eventually died in the hospital.

Patient 4

A 75-year-old woman with severe primary pulmonary hypertension and cardiorenal syndrome started PD due to resistant volume overload. At the admission her eGFR was 36 ml/min/1.73 m². The patient was treated with one glucose 4.25% exchange per day for 2 months. She was edematous therefore icodextrin was added. She continued treatment with furosemide and was on sodium restriction diet. Her urinary sodium was 26 meq/l. After icodextrin start serum sodium dropped from 137.3 to 129 meq/l (average of 3 consecutive values) with the lowest value measured of 128 meq/l. She was reported by her family to be confused. She fell down and broke her hip neck. Icodextrin was stopped during the hospitalization. A month later average serum sodium was 138 meq/l (average of 3 consecutive values). The patient eventually died from complications of orthopedic surgery.

Patient 5

An 85-year-old man with ischemic cardiomyopathy, low LVEF, severe pulmonary hypertension and diabetes mellitus started with peritoneal UF due to refractory volume overload. His eGFR was 43 ml/min/1.73 m² at PD start. He had no proteinuria and normal kidneys in sonography. His kidney disease was attributed to cardiorenal syndrome. He was treated with

one glucose 4.25% exchange per day for 3 month, then icodextrin was added. He continued treatment with furosemide and was on sodium restriction diet. His urinary sodium was 31 meq/l. After icodextrin start serum sodium dropped from 138.3 to 130 meq/l (average of 3 consecutive values) with the lowest value measured of 127 meq/l. Icodextrin was stopped. A month later serum sodium was 138.6 meq/l (average of 3 consecutive values).

Comparison of severe hyponatremia group with mild hyponatremia group

To find out which patients were more susceptible to severe hyponatremia after icodextrin addition we compared the characteristics of the above 5 patients as a group (median serum sodium was 129 meq/l, range 126.3–130 meq/l) with the data of 12 refractory CHF patients who were treated with icodextrin during the same period but their median serum sodium was 134.5 meq/l (range 132.3–136.7 meq/l). Higher SPAP was more likely connected to significant hyponatremia: median SPAP measured 78 mmHg (range 43–92 mmHg) in severe hyponatremia group compared to 49 mmHg (range 37–67 mmHg) in mild hyponatremia group ($p=0.0225$). Patients who developed significant hyponatremia died earlier compared to patients with insignificant hyponatremia. Median survival was 5 months (range 2–7 months) in severe hyponatremia group compared to 15.5 months (range 6–50 months) in mild hyponatremia group ($p=0.0318$). There was a tendency for significant sodium drop in women compared to men: in significant hyponatremia group 60% were women compared to 8% women in mild hyponatremia group ($p=0.0525$).

Patients with lower baseline sodium showed a tendency for a more significant sodium drop compared to those with higher baseline sodium. Baseline serum sodium was 136.3 meq/l (range 133.7–137.3 meq/l) in the severe hyponatremia group compared to 138 meq/l (range 134.3–141 meq/l) in mild hyponatremia group ($p=0.0854$).

There was no difference between the groups in NYHA functional class, diabetes mellitus rate, serum creatinine and albumin levels, baseline urinary sodium or diuretics use.

Discussion

We presented the group of patients who developed clinically relevant hyponatremia following icodextrin addition to the program. Five refractory CHF patients showed serum sodium drop by median of 8 meq/l during the first month of icodextrin treatment, more profound decrease than previously reported (Table 1).^{11–13}

It has been proposed that several mechanisms could explain the development of hyponatremia in PD, including net water gain due to excessive water intake or low ultrafiltration rate of free-water, negative Na⁺/K⁺ balance caused by low Na⁺/K⁺ intake or high Na⁺/K⁺ removal, and shift of intracellular water to extracellular space induced by the use of icodextrin or hypercatabolism and malnutrition.¹⁴

CHF patients had a tendency to low serum sodium level due to neurohumoral activation. The neurohumoral changes limit both sodium and water excretion in an attempt to return perfusion pressure to normal. ADH release directly enhances water reabsorption in the collecting tubules, whereas angiotensin II and norepinephrine limit distal water delivery by reduction in renal perfusion and by increasing proximal sodium and water reabsorption.¹⁵ In addition, both the low cardiac output and high angiotensin II levels are potent stimuli to thirst, leading to enhanced water intake. While significant hyponatremia was temporarily related to icodextrin start, we could not exclude the possibility that hyponatremia in these patients is multifactorial. Probably some of our patients were non-adherent to free water restriction, while others demonstrated hyperglycemia (although corrected serum sodium was also low). Other possible contributors to hyponatremia in those patients are dietary restriction and chronic use of diuretics. The risk factors for hyponatremia were female sex, low initial sodium level and increased SPAP. All patients except one had hypertonic glucose 4.25% in their program which could increase thirst and as a result free water consumption. Perhaps, icodextrin metabolites accumulation rises serum osmolality, stimulates thirst and free water consumption which further contribute to hyponatremia in those severe CHF patients.

In our cases patients with severe hyponatremia had lower survival compared to mild hyponatremia group. The studies demonstrated that severe underlying disease worsens hyponatremia and clinical outcome.¹⁴ Hyponatremia itself may be a surrogate marker for the severity of underlying disease.¹⁴ Hyponatremia is known to be an important marker and prognostic factor of left-sided heart failure.¹⁶ Recently, it was demonstrated that hyponatremia was an indicator of poor prognosis in patients with echocardiographic evidence of

pulmonary hypertension and preserved left ventricular systolic function.¹⁷ Perhaps, patients with certain heart failure etiologies and severe heart disease (as represented by lower survival rate compared to mild hyponatremia group) are more susceptible to this complication.

Two CHF patients who developed significant hyponatremia following icodextrin treatment suffered from hip fracture. There is an emerging literature that suggests that hyponatremia increases the adjusted odds ratio for both falls and fractures in the elderly.¹⁸ Hyponatremia appears to contribute to falls and fractures by two mechanisms: it produces mild cognitive impairment resulting in unsteady gait and falls and it directly contributes to bone impairment through osteoporosis due to increased bone resorption in order to mobilize sodium from the bone or altered bone quality through decreased bone microfracture repair.¹⁸

Conclusions

Hyponatremia in refractory CHF patients is multifactorial. In rare cases, icodextrin may contribute to clinically relevant hyponatremia if the hyponatremia is compounded by other factors. Severe hyponatremia in icodextrin users was associated with poorer survival and is most likely a marker of advanced heart disease. This could be a signal to physician to consider alternative and probably more aggressive interventions.

Conflict of interests

The authors declare they have no conflict of interest.

REFERENCES

1. François K, Ronco C, Bargman JM. Peritoneal dialysis for chronic congestive heart failure. *Blood Purif.* 2015;40:45–52.
2. Lu R, Muciño-Bermejo MJ, Ribeiro LC, Tonini E, Estremadoyro C, Samoni S, et al. Peritoneal dialysis in patients with refractory congestive heart failure: a systematic review. *Cardiorenal Med.* 2015;5:145–56.
3. Basile C, Chimienti D, Bruno A, Cocola S, Libutti P, Teutonico A, et al. Efficacy of peritoneal dialysis with icodextrin in the long-term treatment of refractory congestive heart failure. *Perit Dial Int.* 2009;29:116–8.
4. Bertoli SV, Musetti C, Ciurlino D, Basile C, Galli E, Gambaro G, et al. Peritoneal ultrafiltration in refractory heart failure: a cohort study. *Perit Dial Int.* 2014;34:64–70.
5. Sav T, Inanc MT, Dogan A, Oymak O, Utas C. Two daytime icodextrin exchanges decrease brain natriuretic peptide levels and improve cardiac functions in continuous ambulatory peritoneal dialysis patients. *Nephrology (Carlton).* 2010;15:307–12.
6. Sav T, Oymak O, Inanc MT, Dogan A, Tokgoz B, Utas C. Effects of twice-daily icodextrin administration on blood pressure and left ventricular mass in patients on continuous ambulatory peritoneal dialysis. *Perit Dial Int.* 2009;29:443–9.
7. Viglino G, Neri L, Feola M. Peritoneal ultrafiltration in congestive heart failure—findings reported from its application in clinical practice: a systematic review. *J Nephrol.* 2015;28:29–38.

8. Silver SA, Harel Z, Perl J. Practical considerations when prescribing icodextrin: a narrative review. *Am J Nephrol*. 2014;39:515-27.
9. Gradden CW, Ahmad R, Bell GM. Peritoneal dialysis: new developments and new problems. *Diabet Med*. 2001;18:360-3.
10. Rodriguez-Carmona A, Fontán MP. Sodium removal in patients undergoing CAPD and automated peritoneal dialysis. *Perit Dial Int*. 2002;22:705-13.
11. Mistry C, Gokal R, Peers EM, the MIDAS Study Group. A randomised multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. *Kidney Int*. 1994;46:496-503.
12. Posthuma N, ter Wee PM, Donker AJM, Oe PL, van Dorp W, Verbrugh HA. Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as daytime dwell. *Perit Dial Int*. 1997;6:602-7, 21.
13. Wolfson M, Piraino B, Hamburger RJ, Morton AR. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. *Am J Kidney Dis*. 2002;40:1055-65.
14. Tseng MH, Cheng CJ, Sung CC, Chou YC, Chu P, Chen GS, et al. Hyponatremia is a surrogate marker of poor outcome in peritoneal dialysis-related peritonitis. *BMC Nephrol*. 2014;15:113.
15. Verbrugge FH, Steels P, Grieten L, Nijst P, Tang WH, Mullens W. Hyponatremia in acute decompensated heart failure: depletion versus dilution. *J Am Coll Cardiol*. 2015;65:480-92.
16. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. *Circulation*. 1986;73:257-67.
17. Rabinovitz A, Raiszadeh F, Zolty R. Association of hyponatremia and outcomes in pulmonary hypertension. *J Card Fail*. 2013;19:550-6.
18. Ayus JC, Negri AL, Kalantar-Zadeh K, Moritz ML. Is chronic hyponatremia a novel risk factor for hip fracture in the elderly? *Nephrol Dial Transplant*. 2012;27:3725-31.